RxDoctor Payments Data

Krista Smith

Family · Cumberland, MDNPI 1750680831

Payments from drug & device makers

$811in general payments, 2019–2025

Across 32 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$158
  • AstraZeneca$151
  • Lilly USA, LLC$102
  • Novo Nordisk$76
  • Amgen$70
  • Antares Pharma, Inc.$63
  • plus $191 from 6 others

What the payments were for

  • Food & beverage$811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$811 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$26,750
Medicare patients
246
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$70,777
EliquisApixaban30$46,351
FarxigaDapagliflozin Propanediol22$15,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,506
Breo ElliptaFluticasone/Vilanterol20$11,286
Tresiba Flextouch U-100Insulin Degludec16$8,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,468
Gabapentin68$2,420
Atorvastatin Calcium154$2,411
Rosuvastatin Calcium115$2,299
Lisinopril176$1,709
Duloxetine Hcl35$1,701
Metformin Hcl155$1,578
Celecoxib20$1,464
Amlodipine Besylate155$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$70,77750 claims
GSKTrelegy Ellipta, Breo Ellipta$17$25,79235 claims
AstraZenecaFarxiga$151$15,68622 claims
AbbVieSynthroid$55$90518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,843 family providers in Maryland.

Other family in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →